Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis
PJ Mease - Current opinion in rheumatology, 2015 - journals.lww.com
PJ Mease
Current opinion in rheumatology, 2015•journals.lww.comThis article reviews the relevant biology, efficacy and safety of new medications targeting the
TH17 pathway, including inhibition of IL17 and IL23, particularly in psoriasis and psoriatic
arthritis. Especially for patients who have not gained benefit from, lost effectiveness to or
could not use antitumour necrosis factor (TNF) medications for safety or tolerability reasons,
having effective medicines with an alternative mechanism of action will improve our ability to
diminish disease activity impact on patient lives.
TH17 pathway, including inhibition of IL17 and IL23, particularly in psoriasis and psoriatic
arthritis. Especially for patients who have not gained benefit from, lost effectiveness to or
could not use antitumour necrosis factor (TNF) medications for safety or tolerability reasons,
having effective medicines with an alternative mechanism of action will improve our ability to
diminish disease activity impact on patient lives.
Summary
This article reviews the relevant biology, efficacy and safety of new medications targeting the TH17 pathway, including inhibition of IL17 and IL23, particularly in psoriasis and psoriatic arthritis. Especially for patients who have not gained benefit from, lost effectiveness to or could not use antitumour necrosis factor (TNF) medications for safety or tolerability reasons, having effective medicines with an alternative mechanism of action will improve our ability to diminish disease activity impact on patient lives.
Lippincott Williams & Wilkins